Trade

with

Pacira Pharmaceuticals Inc
(NASDAQ: PCRX)
AdChoices
101.65
-2.78
-2.66%
After Hours :
101.65
0.00
0.00%

Open

106.45

Previous Close

104.43

Volume (Avg)

513.91k (445.88k)

Day's Range

100.54-106.73

52Wk Range

45.68-109.94

Market Cap.

3.65B

Dividend Rate ( Yield )

-

Beta

1.63

Shares Outstanding

35.89M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Major
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 85.55M

    • Net Income

    • -63.91M

    • Market Cap.

    • 3.65B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -30.75

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.63

    • Forward P/E

    • 38.17

    • Price/Sales

    • 24.57

    • Price/Book Value

    • 24.63

    • Price/Cash flow

    • -277.78

      • EBITDA

      • -51.35M

      • Return on Capital %

      • -18.39

      • Return on Equity %

      • -41.77

      • Return on Assets %

      • -18.39

      • Book Value/Share

      • 4.12

      • Shares Outstanding

      • 35.89M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 114.00

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • 2.39

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 175.20

          • 0.89

          • Net Income

            YTD/YTD (last year)

          • -

          • 7.80

          • Net Income

            Q/Q (last year)

          • -

          • 4.50

          • Sales (Revenue)

            5-Year Annual Average

          • 43.78

          • 6.10

          • Net Income

            5-Year Annual Average

          • -

          • 3.73

          • Dividends

            5-Year Annual Average

          • -

          • 2.17

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 49.34

            • 69.92

            • Pre-Tax Margin

            • -30.75

            • 21.84

            • Net Profit Margin

            • -30.75

            • 18.37

            • Average Gross Margin

              5-Year Annual Average

            • 16.20

            • 71.90

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 21.92

            • Average Net Profit Margin

              5-Year Annual Average

            • -176.50

            • 903.40B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.32

              • Current Ratio

              • 1.61

              • 1.92

              • Quick Ratio

              • 1.42

              • 1.31

              • Interest Coverage

              • -4.40

              • 17.64

              • Leverage Ratio

              • 1.97

              • 2.03

              • Book Value/Share

              • 4.12

              • 14.72

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -80.65

                • 21.41

                • P/E Ratio 5-Year High

                • -86.49

                • 193.96

                • P/E Ratio 5-Year Low

                • -4.85

                • 87.26

                • Price/Sales Ratio

                • 24.88

                • 3.63

                • Price/Book Value

                • 24.94

                • 3.62

                • Price/Cash Flow Ratio

                • -277.78

                • 13.57

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -41.77

                    (-)

                  • 17.42

                    (18.66)

                  • Return on Assets %

                    (5-Year Average)

                  • -18.39

                    (-51.20)

                  • 8.45

                    (8.77)

                  • Return on Capital %

                    (5-Year Average)

                  • -17.23

                    (-)

                  • 12.41

                    (13.18)

                  • Income/Employee

                  • -

                  • 90.07k

                  • Inventory Turnover

                  • 4.26

                  • 2.46

                  • Asset Turnover

                  • 0.60

                  • 0.46

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -53.29M
                  Operating Margin
                  -62.29
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -277.78
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  61.42%

                  Mutual Fund Ownership

                  61.67%

                  Float

                  58.54%

                  5% / Insider Ownership

                  0.27%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,266,200

                  • 4.15

                  • 3.53

                  • T. Rowe Price Small Cap Stock Fund

                  •  

                    1,208,900

                  • -0.49

                  • 3.37

                  • T. Rowe Price New Horizons Fund

                  •  

                    1,086,800

                  • 4.38

                  • 3.03

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    957,533

                  • 0.00

                  • 2.67

                  • Fidelity® Capital Appreciation Fund

                  •  

                    872,522

                  • 0.00

                  • 2.43

                  • ClearBridge Small Cap Growth Fund

                  •  

                    784,903

                  • 37.99

                  • 2.19

                  • Prudential Jennison Health Sciences

                  •  

                    728,540

                  • -1.23

                  • 2.03

                  • Vanguard Small Cap Index

                  •  

                    592,335

                  • 0.34

                  • 1.65

                  • iShares Russell 2000 (AU)

                  •  

                    558,520

                  • -1.01

                  • 1.63

                  • Vanguard Total Stock Mkt Idx

                  •  

                    554,467

                  • 1.08

                  • 1.54

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • T. Rowe Price Associates, Inc.

                  •  

                    4,726,726

                  • +1.71%

                  • 13.19

                  • Gilder Gagnon Howe & CO LLC

                  •  

                    3,273,703

                  • -3.97%

                  • 9.13

                  • Fidelity Management and Research Company

                  •  

                    3,100,234

                  • -0.93%

                  • 8.65

                  • Jennison Associates LLC

                  •  

                    2,529,910

                  • -3.91%

                  • 7.06

                  • Vanguard Group, Inc.

                  •  

                    2,080,115

                  • +6.33%

                  • 5.80

                  • Hbm Bioventures Cayman Ltd

                  •  

                    1,667,307

                  • +2.23%

                  • 4.95

                  • BlackRock Fund Advisors

                  •  

                    1,354,524

                  • +9.53%

                  • 3.78

                  • Daruma Asset Management Inc

                  •  

                    1,132,552

                  • -17.39%

                  • 3.16

                  • Marsico Capital Management, LLC

                  •  

                    1,076,384

                  • +14.25%

                  • 3.00

                  • Next Century Growth Investors LLC

                  •  

                    967,638

                  • -19.38%

                  • 2.70

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Major

                  Type

                  Speculative Growth

                  Style

                  Small Growth

                  Pacira Pharmaceuticals, Inc. was incorporated in Delaware under the name Blue Acquisition Corp. in December 2006 and changed its name to Pacira, Inc. in June 2007. The Company is a pharmaceutical company engaged in the development, c...moreommercialization and manufacture of proprietary pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. As of December 31, 2013, its commercial stage products are EXPAREL and DepoCyt. EXPAREL is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated for administration into the surgical site to produce postsurgical analgesia and was approved by the FDA on October 28, 2011. The Company commercially launched EXPAREL in April 2012. It ship EXPAREL directly to the end use...morer based on orders placed to wholesalers or directly to the Company and have no product held by wholesalers. DepoCyt is a sustained release liposomal formulation of the chemotherapeutic agent cytarabine and is indicated for the intrathecal treatment of lymphomatous meningitis. DepoCyt was granted accelerated approval by the FDA in 1999 and full approval in 2007. The Company sells DepoCyt to its commercial partners located in the U.S. and Europe. The Company’s trademarks include Pacira, EXPAREL, DepoCyt and DepoCyte. The Company’s customers are AmerisourceBergen Health Corporation, Cardinal Health, Inc. and McKesson Drug Company. Its competitors include organizations such as multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and generic drug companies. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling, release and disposal of, and exposure to, these hazardous materials. In addition to regulations in the United States, it is subject to various foreign regulations governing clinical trials and the commercial sales and distribution of its products.lessless

                  Key People

                  David M. Stack

                  CEO/Director/President/Chairman of the Board

                  James S. (Jim) Scibetta

                  CFO/Senior VP/Secretary

                  Dr. Gary W. Pace,PhD

                  Director

                  Dr. Yvonne Greenstreet,M.D.

                  Director

                  John P. Longenecker,PhD

                  Director

                  • Pacira Pharmaceuticals Inc

                  • 5 Sylvan Way

                  • Parsippany, NJ 07054

                  • USA.Map

                  • Phone: +1 973 254-3560

                  • Fax: -

                  • pacira.com

                  Incorporated

                  2006

                  Employees

                  310

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: